Leiden, The Netherlands – DCPrime B.V., a clinical stage company dedicated to developing cancer vaccines based on its proprietary DCOne® platform, announces the publication of a peer-reviewed research paper which documents that its lead product DCP-001 can induce T cell activation and myeloma-specific immunity in peripheral blood mononuclear cells from patients with Multiple Myeloma (MM). This preclinical study was part of a collaboration with Prof Dr David Avigan, Beth Israel Deaconess Medical Center, Harvard, Boston and sets the stage for further clinical development of DCP-001 as an immunotherapeutic against MM.
The paper has been published in the Journal of Immunotherapy, by Leaf et al.
About DCPrime
DCPrime is a privately owned, clinical stage biotechnology company focused on developing therapeutic, dendritic cell-based cancer vaccines. DCPrime’s technology platform is based on the DCOne® cell line, which is derived from myeloid leukemia cells and expresses a number of validated tumor antigens. This makes the platform suitable for application in patients with myeloid and other hematological cancers. In addition, DCOne® cells can be loaded with tumor associated antigens of choice, to develop cancer-specific vaccine formulations for multiple other (solid) cancer types. The company’s lead product DCP-001 is positioned as a consolidation vaccine therapy in Acute Myeloid Leukemia (AML). A Phase I/IIa study with this product has been completed and shows that DCP-001 is a safe product that induces a clear anti-tumor response in patients, and strong survival improvement in several of the studied patients. DCPrime received orphan drug designation in AML for this product from the EMA and is currently preparing a multi-center Phase II trial to demonstrate efficacy in AML patients.